June 2nd 2023
In a real-world population of patients with relapsed or refractory B-cell acute lymphoblastic leukemia, modest efficacy was demonstrated with brexucabtagene autoleucel.
February 27th 2023
FDA Grants Fast Track and Rare Pediatric Disease Designations for WU-CART-007 in T-ALL/LBLJuly 20th 2022
The FDA has granted fast track designation and rare pediatric disease designation for WU-CART-007 as treatment for patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma.
Quizartinib Combined with Chemotherapy Doubles OS Compared with Chemotherapy Alone in Patients with FLT3-ITD–Positive AMLJune 13th 2022
Quizartinib with standard induction and consolidation chemotherapy followed by continued quizartinib monotherapy treatment led to significant improvement in overall survival in patients with newly diagnosed FLT3-ITD–positive acute myeloid leukemia.
Matched Sibling Donor Transplant Improves 2-Year Overall Survival in R/R ALLApril 26th 2022
Retrospective data signal that transplant with a matched sibling donor may prolong survival over haploidentical stem cell transplant in patients with relapsed or refractory acute myeloid leukemia.
Biomarkers Accumulate in the Acute Myeloid Leukemia ParadigmApril 26th 2022
In an interview with Targeted Oncology, Eytan M. Stein, MD, hematologic oncologist from Memorial Sloan Kettering Cancer Center, discusses the latest treatment developments and updates within the AML space.
FDA Approval Application for U2 Regimen in CLL and SLL Voluntarily WithdrawnApril 18th 2022
With an increasing imbalance in overall survival, the FDA approval application for the combination of ublituximab and umbralisib for the treatment of adult patients with chronic lymphocytic leukemia and small lymphocytic lymphoma has been withdrawn.
FDA Halts Phase 1/2 Study of Emavusertib in Patients With Relapsed/Refractory AMLApril 4th 2022
The phase 1/2 TakeAim Leukemia study exploring emavusertib in patients with acute myeloid leukemia and myelodysplastic syndrome has been halted by the FDA pending more safety and efficacy data.
Lymphodepletion Improves Results for Allogenic CAR T-Cell Therapy in ALLJanuary 7th 2022
Nitin Jain, MD, discusses the preliminary results of a study investigating allogeneic chimeric antigen receptor T-cell therapy with lymphodepletion in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Improved Sensitivity, Monitoring Needed for MRD in Adult and Pediatric ALLOctober 18th 2021
Despite advances with MRD monitoring, further research and practice advances are needed to continue the trend for improving outcomes in patients with acute lymphoblastic leukemia.